IL263896A - T cell compositions for immunotherapy - Google Patents

T cell compositions for immunotherapy

Info

Publication number
IL263896A
IL263896A IL263896A IL26389618A IL263896A IL 263896 A IL263896 A IL 263896A IL 263896 A IL263896 A IL 263896A IL 26389618 A IL26389618 A IL 26389618A IL 263896 A IL263896 A IL 263896A
Authority
IL
Israel
Prior art keywords
immunotherapy
cell preparations
preparations
cell
Prior art date
Application number
IL263896A
Other languages
English (en)
Hebrew (he)
Original Assignee
Geneius Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneius Biotechnology Inc filed Critical Geneius Biotechnology Inc
Publication of IL263896A publication Critical patent/IL263896A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL263896A 2016-06-28 2018-12-23 T cell compositions for immunotherapy IL263896A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662355533P 2016-06-28 2016-06-28
US201662355506P 2016-06-28 2016-06-28
US201662355458P 2016-06-28 2016-06-28
PCT/US2017/039846 WO2018005712A1 (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Publications (1)

Publication Number Publication Date
IL263896A true IL263896A (en) 2019-01-31

Family

ID=60787739

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263896A IL263896A (en) 2016-06-28 2018-12-23 T cell compositions for immunotherapy

Country Status (11)

Country Link
US (2) US20200237819A1 (enExample)
EP (1) EP3487990A4 (enExample)
JP (3) JP7034955B2 (enExample)
KR (1) KR20190037243A (enExample)
CN (1) CN109715788A (enExample)
AU (2) AU2017290119A1 (enExample)
CA (1) CA3068387A1 (enExample)
IL (1) IL263896A (enExample)
MX (1) MX2019000180A (enExample)
SG (1) SG11201811745UA (enExample)
WO (1) WO2018005712A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028531A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
AU2016235388B2 (en) * 2015-03-20 2022-02-03 Children's National Medical Center Generating virus or other antigen-specific T cells from a naive T cell population
DK3532607T3 (da) 2016-10-26 2024-04-02 Iovance Biotherapeutics Inc Restimulation af kryokonserverede, tumorinfiltrerende lymfocytter
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3541930A1 (en) 2016-11-17 2019-09-25 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
EP4053268B1 (en) 2017-01-20 2025-10-08 Kyoto University Method for producing cd8alpha+beta+cytotoxic t cells
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
TW201930340A (zh) * 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP7198602B2 (ja) * 2018-07-11 2023-01-04 カワサキモータース株式会社 自動二輪車
WO2020027094A1 (ja) * 2018-07-31 2020-02-06 サイアス株式会社 ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
EP3830249A1 (en) * 2018-07-31 2021-06-09 polybliocept GmbH Production and selection of tumor uber reactive immune cells (turics)
EP3834833A4 (en) * 2018-08-10 2022-05-18 Eutilex Co., Ltd. Cancer antigen-specific cytotoxic t cells
WO2020032782A1 (ko) * 2018-08-10 2020-02-13 주식회사 유틸렉스 암항원 특이적 cd8+ t 세포의 제조 및 동결보존 방법
WO2020085480A1 (ja) * 2018-10-26 2020-04-30 キッセイ薬品工業株式会社 高効率な遺伝子改変細胞の作製方法
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
KR20210091213A (ko) 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
AU2019403263A1 (en) * 2018-12-18 2021-07-01 Beth Israel Deaconess Medical Center, Inc. Generation of organoid-primed T (opT) cells with memory phenotype
CA3126066A1 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
BR112021015750A2 (pt) * 2019-02-14 2021-10-26 Research Institute At Nationwide Children's Hospital Uso de um agente estimulante para testar a potência de células imunes
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
WO2020243729A1 (en) * 2019-05-31 2020-12-03 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
US20230032934A1 (en) * 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
WO2021133667A1 (en) * 2019-12-23 2021-07-01 Baylor College Of Medicine T cell performance assay as a prognostic factor for clinical outcome
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
KR20230125204A (ko) * 2020-11-25 2023-08-29 지니우스 바이오테크놀로지 인코포레이티드 항원 특이적인 t 세포 및 이의 제조 및 이용 방법
CN113481157B (zh) * 2021-07-21 2023-03-17 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法
CN113564116B (zh) * 2021-07-21 2023-08-01 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
CN113512529B (zh) * 2021-07-21 2022-11-25 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
US20250130220A1 (en) * 2021-09-08 2025-04-24 KSQ Therapeutics, Inc. Lymphocyte potency assay
EP4412628A1 (en) * 2021-10-08 2024-08-14 Baylor College of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
JP2023064787A (ja) * 2021-10-27 2023-05-12 国立大学法人京都大学 Ｔ細胞の品質評価方法、および当該方法に用いる試薬
US20250223552A1 (en) * 2022-03-18 2025-07-10 St. Jude Children's Research Hospital, Inc. Method for preparing t cells for adoptive t cell therapy
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941150D1 (de) * 1998-05-11 2009-09-03 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen-spezifischen t-zellen
MXPA05001044A (es) 2002-08-08 2005-06-22 Baylor College Medicine Aislamiento e identificacion de celulas t.
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
WO2011028531A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2011146473A1 (en) * 2010-05-17 2011-11-24 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
EP2714072A1 (en) 2011-05-26 2014-04-09 Geneius Biotechnology Investments, LLC Modulated immunodominance therapy
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
WO2016033690A1 (en) 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
EP3234130B1 (en) * 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive

Also Published As

Publication number Publication date
EP3487990A4 (en) 2020-07-29
EP3487990A1 (en) 2019-05-29
JP7034955B2 (ja) 2022-03-14
KR20190037243A (ko) 2019-04-05
CA3068387A1 (en) 2018-01-04
US20200237819A1 (en) 2020-07-30
SG11201811745UA (en) 2019-01-30
AU2017290119A1 (en) 2019-01-24
WO2018005712A1 (en) 2018-01-04
JP2022066355A (ja) 2022-04-28
JP2024103547A (ja) 2024-08-01
CN109715788A (zh) 2019-05-03
JP2019519246A (ja) 2019-07-11
AU2023254998A1 (en) 2023-11-16
US20230145991A1 (en) 2023-05-11
MX2019000180A (es) 2019-11-05

Similar Documents

Publication Publication Date Title
IL263896A (en) T cell compositions for immunotherapy
IL281863A (en) Pharmaceutical compositions comprising meloxicam
IL282304A (en) Topical pharmaceutical compositions
IL282225A (en) Compositions and methods for immunotherapy
IL284348A (en) Hiv pre-immunization and immunotherapy
IL249313A0 (en) Improved t cell compositions
IL253341B (en) Methods and compositions for combination immunotherapy
EP3624810A4 (en) NANO-ACTIVATED IMMUNOTHERAPY FOR CANCER DISEASES
IL261316A (en) Compositions and methods for cd20 immunotherapy
IL263834A (en) Anti-pd-l1 antibodies
IL261271A (en) Methods for making l-glufosinate
HRP20180501T1 (hr) Pripravci koje sadrže bakterijske sojeve
HUE055742T2 (hu) Gyorsan ható inzulin készítmények
HUE058288T2 (hu) Pridopidin módosított hatóanyag-leadású készítményei
HUE053347T2 (hu) Glikopeptid-készítmények
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
DK3377618T3 (da) Buffere til stabilisering af lentivirus-præparater
DK3452507T3 (da) Tau-immunoterapi
IL261341B (en) Branch instruction
HUE045024T2 (hu) Poliamid készítmények
EP3592839C0 (en) MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY
PL3512537T3 (pl) Immunoterapia limfocytami t
DK3529262T3 (da) Fremgangsmåder til fremme af t-cellerespons
HUE053624T2 (hu) Ciklosporint tartalmazó készítmények
EP3310915A4 (en) TUMOR IMMUNOTHERAPY